Diabetic cardiomyopathy (DCM) is a clinically significant complication of diabetes mellitus characterized by ventricular hypertrophy, progressive fibrosis, and impaired cardiac performance that occurs independently of other cardiovascular conditions. Recent research has highlighted a central role for non-coding RNAs (ncRNAs) in the biology of DCM. The major ncRNA classes implicated are microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs). This review consolidates mechanistic evidence linking ncRNAs to DCM and evaluates their diagnostic, prognostic, and therapeutic implications based on the available literature.
Accumulating experimental data indicate that ncRNAs modulate multiple pathological processes that drive DCM. Key mechanisms influenced by ncRNAs include:
Cardiac hypertrophy: ncRNAs participate in signaling networks that regulate cardiomyocyte growth and ventricular remodeling, contributing to hypertrophic changes observed in DCM.
Apoptosis: dysregulated ncRNA expression affects pathways controlling cardiomyocyte survival and programmed cell death, thereby influencing cardiomyocyte loss.
Oxidative stress: ncRNAs have been linked to the regulation of oxidative stress responses in diabetic hearts, which is a major contributor to cellular injury.
Inflammation: ncRNAs modulate inflammatory signaling cascades that promote adverse cardiac remodeling and functional decline.
Mitochondrial dysfunction: ncRNA-mediated regulation of mitochondrial biology can affect energy production and reactive oxygen species generation, processes central to DCM pathology.
These mechanistic roles are supported by a growing number of individual studies examining specific ncRNAs in experimental models. The evidence shows that different ncRNA species interact with molecular pathways relevant to hypertrophy, fibrosis, cell death, inflammation, and mitochondrial impairment. However, these findings are dispersed across disparate reports, underscoring the need for integrated synthesis and comparative evaluation.
Several features of ncRNAs make them attractive candidate biomarkers for DCM. Notably, many ncRNAs demonstrate relative stability in biological fluids and exhibit tissue-specific expression patterns, enhancing their potential utility as non-invasive diagnostic or prognostic indicators. The review consolidates studies that have evaluated ncRNA expression profiles in the context of diabetic cardiac disease and highlights the possibility that selected ncRNAs could serve as biomarkers for early detection, disease staging, or risk stratification.
Nevertheless, while individual reports describe diagnostic or prognostic associations, the body of evidence remains heterogeneous. The review emphasizes that robust, large-scale validation studies are required to confirm the sensitivity, specificity, and clinical utility of ncRNA-based biomarkers in DCM before routine clinical application.
Experimental modulation of dysregulated ncRNAs has produced functional improvements in animal and cellular models of DCM. These interventions aim either to restore protective ncRNA activity or to inhibit pathogenic ncRNA signaling. The review synthesizes findings showing that such approaches can ameliorate cardiac dysfunction and remodeling in preclinical settings, supporting the concept that ncRNAs may be viable therapeutic targets.
Despite promising preclinical results, the review cautions that translational challenges remain. Critical issues include demonstrating reproducible efficacy across models, establishing safety and delivery strategies for ncRNA-targeted agents, and performing comprehensive validation in larger, well-controlled studies prior to human trials.
The authors note several gaps in the current literature: study findings are scattered, and many reports are limited to individual experimental systems rather than large cohorts or multicenter validations. Key priorities identified include:
Standardized validation of candidate ncRNA biomarkers in large-scale clinical and translational studies.
Comparative assessments to determine which ncRNAs offer the most reliable diagnostic or prognostic value.
Advancement of therapeutic development with rigorous evaluation of delivery platforms, off-target effects, and long-term outcomes in appropriate models.
The review aims to guide future biomarker validation and therapeutic development by consolidating mechanistic insights and highlighting areas requiring focused research.
Non-coding RNAs — notably miRNAs, lncRNAs, and circRNAs — play multifaceted roles in the pathogenesis of diabetic cardiomyopathy by regulating hypertrophy, apoptosis, oxidative stress, inflammation, and mitochondrial dysfunction. Their stability and tissue-specific expression make them promising candidates for non-invasive diagnostic and prognostic biomarkers. Preclinical modulation of dysregulated ncRNAs has produced improvements in cardiac function, supporting therapeutic potential. However, the authors emphasize that further large-scale validation is necessary before ncRNA-based biomarkers or therapies can be translated into clinical practice.
(Details such as specific ncRNA names, experimental protocols, quantitative outcomes, and study-level data were not reported in the source abstract and would require consultation of the full text for precise information.)